Skin cancer is the most common type of cancer in the United States, with millions of cases diagnosed each year. According to the National Institutes of Health (NIH), basal cell carcinoma and squamous cell carcinoma are the most frequently occurring forms, with over 4 million and 1 million cases annually, respectively.
Health Professionals
First patient treated in new phase II clinical trial at Radiumhospitalet in Oslo – promising use of Lytix cancer treatment in patients with early-stage melanoma
Oslo, Norway, November 6, 2024 – Lytix Biopharma, a Norwegian immuno-oncology company dedicated to being part of tomorrow’s cancer treatment, announces that the first patient has been treated in a new Phase II trial (NeoLIPA). The study evaluates the effect of Lytix’s lead drug candidate, LTX-315, in early-stage patients diagnosed with melanoma. Melanoma is the most severe type of skin cancer with a rising incidence globally and an estimated global market of USD 11 billion by 2030.
Heart Transplant Recipients May Have a Significantly Higher Melanoma Risk
Patients who have received a heart transplant have a significantly increased risk for melanoma compared with the general population, according to study results published in Melanoma Research.
Dr. John Fruehauf on a New Standard of Care for Stage III Melanoma
Dr. John Fruehauf, field medical director at Evolent, and specialist in melanoma, spoke to DocWire News about some of the challenges associated with treating melanoma in stage III disease, and about the NADINA trial, which demonstrated the robust efficacy of neoadjuvant nivolumab in combination with ipilimumab in the treatment of stage III melanoma. The trial findings, which Dr. Fruehauf details, represent a new standard of care in melanoma.